Bicycle Therapeutics plans dose selection update in first quarter 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026
January 12, 2026 7:00 AM ESTDose selection from Phase 2/3 Duravelo-2 trial and update on potential approval pathway expected in 1Q 2026 as company seeks feedback from multiple regulatory agencies
Emerging radiopharmaceuticals pipeline progressing, with additional EphA2 human imaging data planned for the first half of 2026
Initial data for Phase 1/2 Duravelo-3 trial exploring zelenectide pevedotin in NECTIN4 amplified breast cancer expected in the second half of 2026
Expected financial runway into 2028 to support execution of clinical and strategic priorities
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ:... More
